Treatment of Metastatic Anal Cancer with Solitary Liver Metastasis
For this 51-year-old woman with a solitary 3-cm liver metastasis from anal cancer, first-line systemic chemotherapy with carboplatin plus paclitaxel is the preferred treatment, with consideration of liver-directed therapy (resection or ablation) if she achieves good disease control. 1
Primary Treatment Approach: Systemic Chemotherapy
First-Line Regimen
Carboplatin plus paclitaxel is the standard of care for chemotherapy-naive metastatic anal cancer based on the InterAACT trial, which demonstrated superior overall survival (20 months vs 12.3 months) and lower toxicity compared to cisplatin/5-FU. 2, 1
This regimen showed a 59% objective response rate with significantly fewer serious adverse events (36% vs 62%, P=0.016) compared to cisplatin/5-FU. 1
The hazard ratio for overall survival favored carboplatin/paclitaxel at 2.0 (95% CI 1.15-3.47, P=0.014). 2, 1
Alternative Chemotherapy Options
If carboplatin/paclitaxel is contraindicated or not tolerated, consider:
FOLFCIS (5-FU, leucovorin, cisplatin) - demonstrated 48% response rate with median OS of 22.1 months in retrospective analysis. 1
FOLFOX (5-FU, leucovorin, oxaliplatin) - safe alternative with documented efficacy. 1
Modified DCF (docetaxel, cisplatin, 5-FU) - category 2B recommendation showing encouraging activity in phase II trials. 2, 1
Cisplatin plus 5-FU - category 2B due to similar efficacy but higher toxicity compared to carboplatin/paclitaxel. 1
Critical Consideration: Liver-Directed Therapy
A solitary 3-cm liver metastasis may be amenable to surgical resection or ablation after initial systemic therapy. 1
A retrospective analysis of 106 patients demonstrated that resection or ablation of liver metastases can result in long-term survival, with patients with anal cancer having better outcomes than those with non-anal squamous cell carcinoma. 1
One case report documented successful treatment with induction chemotherapy (cisplatin/5-FU) followed by liver resection and radiation to the anal primary, resulting in disease control at 19 months without increased toxicity. 3
This approach is not currently included in NCCN Guidelines but represents a reasonable option for carefully selected patients with solitary, resectable metastases who respond to initial chemotherapy. 1
Recommended Treatment Algorithm
Initiate carboplatin/paclitaxel chemotherapy as first-line treatment. 1
Reassess after 2-3 cycles with imaging to evaluate response and resectability of the liver lesion. 1
If good response achieved and liver metastasis remains solitary and resectable, consider multidisciplinary evaluation for liver resection or ablation. 1, 3
Continue systemic therapy for total of 4-6 cycles if pursuing non-surgical approach, or perioperatively if pursuing resection. 1
Important Caveats
Prior Treatment Considerations
This patient previously received mitomycin and 5-FU with radiation, which is relevant because some second-line data exists for re-challenging with mitomycin/5-FU in the metastatic setting. 4
However, given she is chemotherapy-naive in the metastatic setting, carboplatin/paclitaxel remains the preferred first-line option rather than re-using her prior regimen. 1
One study showed mitomycin/5-FU as second-line therapy achieved 26.4% objective response rate with median PFS of 3 months, but this is inferior to first-line carboplatin/paclitaxel. 4
Role of Radiation Therapy
Palliative chemoradiotherapy to the primary site can be considered after upfront chemotherapy if there is symptomatic bulky primary disease requiring local control. 1
National Cancer Database analysis showed patients with newly diagnosed metastatic anal cancer receiving definitive pelvic RT plus chemotherapy had longer median OS than chemotherapy alone (21.3 vs 15.9 months, HR 0.70, P<0.001). 1
However, this patient already received definitive chemoradiation, so this consideration is less relevant unless there is local recurrence. 1